(PharmaNewsWire.Com, January 23, 2018 ) In this region, global cancer diagnostics is projected to reach USD 40.10 billion by 2024 from USD 16.55 billion in 2016, at a CAGR of 11.7% in the forecast period 2017 to 2024.
Based on geography, the global cancer diagnostics market is segmented into 5 geographical regions, such as, North America, South America, Europe, APAC, MEA, Rest Of the World
GE Healthcare is going to dominate the cancer diagnostics market, by imaging following with Siemens Healthcare GmbH along with others such as Hologic, Inc, Becton, Dickinson & Company.
Thermo Fisher Scientific, Inc. is going to dominate the cancer diagnostics market, by platform based following with Illumina, Inc. along with others such as
Roche Diagnostics, Abbott Laboratories, Inc. Qiagen.
The global cancer diagnostics market is segmented into 2 types, namely platform based and instrument based. Cancer diagnostics platform based market is segmented into Polymerase Chain Reaction (PCR), In Situ Hybridization (ISH), Immunohistochemistry (IHC), Next Generation Sequencing (NGS), DNA microarrays, flow cytometry and others. Cancer Diagnostics instrument based market is segmented into imaging and biopsy. Imaging is further segmented into Magnetic Resonance Imaging (MRI), Computed Tomography (CT), Positron Emission Tomography- Computed Tomography (PET-CT), mammography and ultrasound.
Table of Contents:
1. Introduction
2 Market Segmentation
3. arket Overview 4 Executive Summary
5 Premium Insights
7 Global Aromatherapy Market, By Equipment
8 Global Aromatherapy Market, By Application
9. Global Aromatherapy Market, By Distribution Channel
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
